Table 2. Key data of the study intervention.
| Group | Xenon (n = 93) | Sevoflurane (n = 94) | P |
|---|---|---|---|
| Surgery visc/gyn/uro [n] (%) | 6/50/37 (6/54/40) | 3/60/31 (3/64/33) | 0.296 |
| Epidural none/lumb/thor [n] (%) | 68/4/21 (73/4/23) | 73/2/19 (78/2/20) | 0.625 |
| Anesthesia duration [min] | 141.7 ± 60.3 | 145.3 ± 62.3 | 0.688 |
| PACU stay [min] | 94.6 ± 56.9 | 80.4 ± 40.4 | 0.050 |
| ∑ Propofol [mg kg-1] | 3.0 ± 1.0 | 2.3 ± 0.6 | 0.000 |
| Ø FiO2 | 0.44 ± 0.06 | 0.51 ± 0.12 | 0.000 |
| Ø FiAnesthetic [%] (MAC) | 56 ± 5 (0.9) | 1.8 ± 0.4 (1.0) | - |
| Ø Remifentanil [μg kg-1 min-1] | 0.19 ± 0.06 | 0.18 ± 0.06 | 0.046 |
| Ø Piritramide (An) [mg kg-1] | 0.08 ± 0.05 | 0.07 ± 0.04 | 0.178 |
| Ø Piritramide (PACU) [mg kg-1] | 0.08 ± 0.08 | 0.09 ± 0.08 | 0.580 |
Key data of the study intervention are demonstrated in Table 2. The length of anesthesia and PACU stay, the total amount (Σ) of propofol, the average values (Ψ) of inspiratory oxygen fraction (FiO2) and anesthetic concentration (FiAnesthetic), the average remifentanil and piritramide doses administered during general anesthesia (An) and during PACU stay are presented as mean ± SD. The FiAnesthetic as a fraction of its individual minimal alveolar concentration (MAC) is presented in parentheses. The surgery type (visc visceral/ gyn gynecological/ uro urological) and an optional additional epidural anesthesia (none/ lumb lumbar/ thor thoracic) are given as numbers and percent of total.